RSS Almirall

Almirall awarded the �zero rate� for accident frequency in 2009

Wed, 08 Sep 2010

The pharmaceutical company has been awarded the COASHIQ award for reducing its accident...

First Half 2010 in line with guidance, strong R&D catalysts expected in second half

Fri, 30 Jul 2010

See attached .pdf

Sativex� receives regulatory authorisation in Spain

Wed, 28 Jul 2010

· Spanish health authorities grant regulatory...

Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza� in Spain, a new therapeutic option to treat osteoporosis

Mon, 26 Jul 2010

This agreement enables Almirall to reinforce its core business in Spain for the coming ...

Almirall reaffirms its commitment to the environment with renewal of its ISO 14001:2004 certificate

Fri, 23 Jul 2010

This certificate endorses the company’s commitment to the environment and i...

The presentation of the Neogenius project brings together around a hundred investigators

Thu, 17 Jun 2010

See attached pdf.

Almirall announces an international agreement with Basilea to commercialize Toctino� (alitretinoin) for severe chronic hand eczema

Tue, 15 Jun 2010

Toctino® is the only therapy approved for adults with severe chronic hand eczema (C...

Regulators in UK and Spain confirm Sativex� is approvable

Thu, 20 May 2010

· Sativex®receives positive recommendatio...

Almirall's Annual General Meeting approves a dividend of 0.33 euros per share, a figure 5% up on last year

Mon, 17 May 2010

The pharmaceutical company allocates over 55 million euros to shareholder dividend paym...

Almirall: First Quarter 2010 on track

Thu, 13 May 2010

See the attached pdf.

Almirall and Forest to present data from studies of Eklira� (aclidinium bromide) in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in asthma

Tue, 11 May 2010

· Data to be presented at 2010 American Thor...

20 years of the antihistamine Ebastel� (ebastine)

Fri, 07 May 2010

An estimated 3 and a half billion units of Ebastel® have been administered[i] ...

Almirall grants Eisai marketing rights to cinitapride in China

Fri, 16 Apr 2010

Almirall continues to expand in Asia through one of its proprietary R&D medicines ...

Almirall launches Thiomucase extreme areas, the first anti-cellulite in a stick for rebellious areas

Tue, 13 Apr 2010

Its formula with lypodualenzym® acts on rebellious cellulite ...

Almirall: Solid performance in 2009, setting basis for sustainable long-term growth

Thu, 25 Feb 2010

Barcelona, 25 February 2010 Solid financial performance in a challenging envi...

NEOGENIUS, the alliance between Almirall, Esteve, Palau Pharma and Proteomika, is to investigate new medicines for the treatment of osteoarthritis-induced pain

Wed, 24 Feb 2010

This new association of national pharmaceutical companies is a clear example of coopera...

A multidisciplinary approach to improve treatment and reduce patient cardiovascular risk

Fri, 12 Feb 2010

The 4th VAM meeting (Vascular Disease: A Multidisciplinary Approach) is to be held on 12 an...

Silodosin, indicated for benign prostatic hyperplasia (BPH), has been approved by the European Commission

Mon, 08 Feb 2010

Barcelona, February, 8th 2010.- Almirall informs that the European Commission has granted a marketi...

Almirall strengthens its focus on the twice-daily dosing of Eklira� in Chronic Obstructive Pulmonary Disease (COPD)

Wed, 27 Jan 2010

· Improved efficacy (trough FEV1) values and good...

The 9th Psychiatry Symposium, organized by Almirall, presents the latest advances in this area

Wed, 20 Jan 2010

Held in Barcelona on January 19th and 20th More than 300 specialists, from ho...

Almirall and Forest announce positive results from the ACCORD COPD I Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)

Thu, 07 Jan 2010

· Top line results of ACCORD COPD I,...

Almirall and Forest Laboratories to expand respiratory collaboration with LAS100977

Thu, 17 Dec 2009

The agreement refers to OD LABA LAS100977, Almirall’s once daily long-acting beta...

Almirall launches Parapres Plus 32� and Parapres Plus Forte� to treat hypertension

Tue, 01 Dec 2009

In Spain only 4 out of every 10 hypertensive patients treated have their arteri...

The EMEA/CHMP adopts a positive opinion for silodosin

Fri, 27 Nov 2009

Barcelona, 27 November 2009.- Further to the recent announcement by Recordati, Almirall is also ple...

Almirall reports net sales of 701.3 million euros, an increase of 2.4%

Mon, 16 Nov 2009

The Dermatology area consolidates its growth with an increase of 12.4% compared to the same p...

Almirall�s DHODH inhibitor recognized in the Windhover top 10 partnering list in the immunology category

Fri, 13 Nov 2009

Almirall’s discovery LAS186323, a DHODH inhibitor for the treatment of rheumatoid...

Almirall announces a US$ 15 M equity investment in Ironwood Pharmaceuticals for linaclotide

Tue, 10 Nov 2009

Linaclotide is a novel option for the treatment of irritable bowel syndrome with consti...

Update on Eklira� (aclidinium bromide) for chronic obstructive pulmonary disease (COPD): Positive results in a short-term comparative trial and announcement of new Phase III studies

Tue, 20 Oct 2009

· Topline positive...

Blastoactiva is the first skin cell repair cream with double A select centella asiatica

Wed, 07 Oct 2009

Almirall enhances it dermatology area with a new dermopharmaceutical product to activat...

Almirall and the Spanish Society of Pharmacology present the 8th Pharmacology Award 2009 in Seville

Fri, 18 Sep 2009

The award was presented during the Spanish Society of Pharmacology’s Annual...